Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

This Month

- PMLiVE

Johnson & Johnson’s Tecvayli receives FDA approval for reduced dosing in multiple myeloma patients

More than 35,000 cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Johnson & Johnson and Protagonist’s JNJ-2113 shows promise in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Johnson & Johnson’s nipocalimab shows promise in autoimmune disorder studies

The drug is currently being evaluated in patients with gMG and Sjögren’s disease

- PMLiVE

Johnson & Johnson agrees $700m settlement to resolve talcum powder investigations

The deal would resolve US states’ probes into the marketing of its talcum products

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

- PMLiVE

Johnson & Johnson’s attempt to resolve talcum powder lawsuits fails a second time

The company’s subsidiary LTL Management is set to appeal the court’s decision

- PMLiVE

Janssen receives positive CHMP opinion for Talvey in multiple myeloma

More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links